Immunocore (IMCR) vs Immatics N.V. (IMTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunocore (IMCR) has outperformed Immatics N.V. (IMTX) over the past year, losing 14.1% versus a loss of 20.8%. Over five years, IMCR leads with a -22.6% price change compared with -46.2% for IMTX. Immunocore is the larger company by market cap ($1.52 billion vs $1.13 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | IMTX |
|---|---|---|
| Share price | $29.51 | $7.40 |
| Market cap | $1.52B | $1.13B |
| 1-day change | +0.35% | -0.74% |
| YTD return | -15.27% | -29.05% |
| 1-year return | -14.06% | -20.83% |
| 5-year return | -22.61% | -46.21% |
| EPS (TTM) | $-0.36 | $-1.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $12.41 |
| 52-week low | $27.56 | $7.02 |
| Distance from 52-week high | -27.51% | -40.41% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +112.55% | +138.40% |
| Average volume | 447.09K | 595.07K |
| Shares outstanding | 51.50M | 152.23M |
| Employees | 524 | 704 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 704 employees
IMCR vs IMTX FAQ
Which is bigger, Immunocore or Immatics N.V.?
Immunocore (IMCR) is larger, with a market capitalization of $1.52B compared with $1.13B for Immatics N.V. (IMTX).
Which stock has performed better over the past year, IMCR or IMTX?
IMCR returned -14.06% over the past 12 months, compared with -20.83% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Immatics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.